Sartorius Stedim Biotech Statistics

Total Valuation

Sartorius Stedim Biotech has a market cap or net worth of GBP 16.94 billion. The enterprise value is 18.95 billion.

Market Cap	16.94B
Enterprise Value	18.95B

Important Dates

The next estimated earnings date is Monday, January 27, 2025.

Earnings Date	Jan 27, 2025
Ex-Dividend Date	Apr 2, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+3.60%
Shares Change (QoQ)	+3.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	29.47M

Valuation Ratios

The trailing PE ratio is 126.73.

PE Ratio	126.73
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 33.42, with an EV/FCF ratio of 45.22.

EV / Earnings	141.83
EV / Sales	8.19
EV / EBITDA	33.42
EV / EBIT	56.19
EV / FCF	45.22

Financial Position

The company has a current ratio of 2.14, with a Debt / Equity ratio of 0.72.

Current Ratio	2.14
Quick Ratio	1.05
Debt / Equity	0.72
Debt / EBITDA	4.22
Debt / FCF	5.62
Interest Coverage	1.85

Financial Efficiency

Return on equity (ROE) is 5.02% and return on invested capital (ROIC) is 3.78%.

Return on Equity (ROE)	5.02%
Return on Assets (ROA)	3.12%
Return on Capital (ROIC)	3.78%
Revenue Per Employee	225,781
Profits Per Employee	13,256
Employee Count	10,662
Asset Turnover	0.34
Inventory Turnover	1.78

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.31% in the last 52 weeks. The beta is 0.67, so Sartorius Stedim Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	-7.31%
50-Day Moving Average	186.60
200-Day Moving Average	183.89
Relative Strength Index (RSI)	66.38
Average Volume (20 Days)	55,293

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sartorius Stedim Biotech had revenue of GBP 2.28 billion and earned 133.64 million in profits. Earnings per share was 1.40.

Revenue	2.28B
Gross Profit	986.42M
Operating Income	331.94M
Pretax Income	186.90M
Net Income	133.64M
EBITDA	537.32M
EBIT	331.94M
Earnings Per Share (EPS)	1.40

Full Income Statement

Balance Sheet

The company has 401.59 million in cash and 2.36 billion in debt, giving a net cash position of -1.95 billion.

Cash & Cash Equivalents	401.59M
Total Debt	2.36B
Net Cash	-1.95B
Net Cash Per Share	n/a
Equity (Book Value)	3.28B
Book Value Per Share	33.11
Working Capital	717.81M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 720.89 million and capital expenditures -301.74 million, giving a free cash flow of 419.15 million.

Operating Cash Flow	720.89M
Capital Expenditures	-301.74M
Free Cash Flow	419.15M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 43.33%, with operating and profit margins of 14.58% and 5.87%.

Gross Margin	43.33%
Operating Margin	14.58%
Pretax Margin	8.21%
Profit Margin	5.87%
EBITDA Margin	23.60%
EBIT Margin	14.58%
FCF Margin	18.41%

Dividends & Yields

Sartorius Stedim Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	-53.44%
Years of Dividend Growth	n/a
Payout Ratio	41.78%
Buyback Yield	-3.60%
Shareholder Yield	-3.60%
Earnings Yield	0.79%
FCF Yield	2.47%

Dividend Details

Stock Splits

The last stock split was on May 6, 2016. It was a forward split with a ratio of 6.

Last Split Date	May 6, 2016
Split Type	Forward
Split Ratio	6

Scores

Sartorius Stedim Biotech has an Altman Z-Score of 3.98.

Altman Z-Score	3.98
Piotroski F-Score	n/a